[[{“value”:”
**Cogent Biosciences Relocates Headquarters to BXP’s 180 CityPoint in Waltham**
Cogent Biosciences, Inc. has signed a lease for 31,518 square feet of space at 180 CityPoint, a Class A office and life sciences building in Waltham, Massachusetts. The property is owned and operated by BXP (Boston Properties). This move marks a strategic relocation from the company’s former headquarters at 275 Wyman Street, as it gears up for the commercialization of its first biotech product.
Cushman & Wakefield represented Cogent Biosciences in the transaction, with Michael O’Leary, Kevin McNamara, Thomas Ashe, and Ross Gaudet leading the advisory team. BXP was self-represented by Pat Mulvihill, Senior Vice President of Leasing, and Casey Torto, Leasing Manager for the Boston region.
“This headquarters lease underscores the shift of innovative biotech companies coming to Waltham, which offers the high-quality space and accessibility that companies primarily once looked for in Cambridge,” said Kevin McNamara of Cushman & Wakefield. “Cogent will benefit from a state-of-the-art environment that supports the firm’s culture, recruitment efforts, and long-term success.”
BXP recently also signed Amplitude Vascular Systems at 180 CityPoint. That company will relocate from Boston’s Seaport District into 38,000 square feet of space, highlighting the building’s growing appeal for life sciences and biotech firms.
“}]]
